ABSTRACT Background In December 2021, the US Food and Drug Administration issued
emergency use authorization for the combination monoclonal antibodies tixagevimab and …

Background Evusheld (EVS) was authorized by FDA and EMA as pre-exposure prophylaxis
(PrEP) in people at high risk of severe Covid-19 outcomes, including people with Multiple …

Background and objectives B-cell-depleting therapies may affect the development of a
protective immune response following vaccination against SARS-CoV-2. It is important to …

Introduction B-cell-depleting therapies may affect the development of a protective immune
response following vaccination against SARS-CoV-2. It is important to have a different …

Vaccines against the SARS-CoV-2 virus were authorized for use by the Food and Drug
Administration (FDA) in the United States and have proven effective for the prevention of …

Objective: To evaluate the risk of breakthrough symptomatic Coronavirus Disease 2019
(COVID-19) infections after tixagevimab/cilgavimab administration for pre-exposure …

Background Patients with MS and related disorders (pwMSARD) on B-cell depleting
treatments have attenuated immune responses to vaccination and were eligible to receive …

Background In Australia, tixagevimab/cilgavimab 150 mg/150 mg was a government-funded
pre-exposure prophylaxis for COVID-19 people with multiple sclerosis (pwMS) and other …

Background The past 2 years of the COVID-19 pandemic brought with it many unknowns for
patients with immunodeficiency. Because of the concern for severe infection in those with …

Methods An observational cross-sectional study was conducted between May and
November 2023 at the National Guard Hospital, Jeddah, Saudi Arabia. All MS patients …